BERLIN--(BUSINESS WIRE)--Regulatory News:
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces that Bryan Jennings will join NOXXON as Chief Financial Officer (CFO) effective as of November 1, 2021. Mr. Jennings has over 30 years of experience in investment banking, capital raising and corporate finance advisory work, a significant amount of which has been in the healthcare, pharmaceutical and biotech sectors.
Aram Mangasarian, CEO of NOXXON commented: "We are very pleased to announce the appointment of Bryan Jennings to the post of Chief Financial Officer. Bryan brings with him extensive financial experience in the biotech industry with significant skills in capital raising and corporate finance. He will be a real asset for NOXXON as we look to increasingly target investors in the US and progress the company financially, while continuing to focus on improving cancer treatments through our unique approach of targeting the tumor microenvironment."
Bryan Jennings has been CFO at a number of biotech and healthcare companies, including Peptilogics, KAHR Bio, Beren Therapeutics, Rational Vaccines and ChemomAb, where he was responsible for strategy and oversaw all financial, accounting, HR and IR functions. Additionally, he was CFO and CEO at Vista Capital Advisors, a broker dealer based in New York, NY. Prior to this, Mr. Jennings spent 20 years at Morgan Stanley where he was Managing Director, Head of Capital Markets and Risk Management. He has a Masters of Management Degree from Northwestern University, Evanston, Illinois and a Bachelor’s Degree from Williams College, Williamstown, Massachusetts.
Bryan Jennings, CFO of NOXXON commented: "I am very excited to join the outstanding team at NOXXON and contribute to the company's development and success. I believe NOXXON has huge long-term potential given its differentiated technology and strong oncology-focused pipeline. I look forward to contributing to NOXXON’s strategic and financials goals in the very near term."
It is the intention of the Supervisory Board to nominate Mr. Jennings as statutory director of NOXXON Pharma N.V. and to convene an extraordinary general meeting of shareholders in due course.
About NOXXON
NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON’s lead program NOX-A12 has delivered final top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients published at the ESMO conference in September 2020 and in July 2021 the company announced its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck’s Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy has delivered interim data from the first two cohorts showing consistent tumor reductions and objective tumor responses. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX‑E36 in patients with solid tumors. Further information can be found at: www.noxxon.com.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.
Visit NOXXON on LinkedIn and Twitter.
About the GLORIA Study
GLORIA (NCT04121455) is NOXXON’s dose-escalation, phase 1/2 study of NOX-A12 in combination with irradiation in first-line glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy).
About the OPTIMUS Study
OPTIMUS (NCT04901741) is NOXXON’s open-label two-arm phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.
Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.